KRAS and neoplasm: In LUAD cohort, the mutation ratio of KRAS, an oncogene which leads to immune escape in the tumor microenvironment (50), and PTPRD, which affects the tumor proliferation (51), were higher than LUSC also suggests the difference immune response mechanisms.